MedTech Intelligence – Read More

Press Release: MTI Staff was not involved in writing this content

Inspira Technologies has received U.S. Patent approval for its ART500 device. The patent is for low flow rates extracorporeal oxygenation system and methods of use and represents the core technology of the ART500 device, including 16 novel claims, is a key asset in the Company’s strategy to penetrate the $20 billion estimated market for advanced respiratory support, according to the press release. 

The patent provides further protection for the underlying core technology of Inspira’s ART500 system, which is designed to provide extracorporeal oxygenation at low flow rates while maintaining patient safety and treatment efficiency. This capability targets a large, underserved patient population that requires respiratory support but may not be sick enough for traditional, high-flow ECMO systems, significantly expanding the potential market for Inspira’s technology. This approval strengthens Inspira’s intellectual property portfolio and reinforces the Company’s technological leadership in the field of advanced extracorporeal life support, according to the company.

The post Inspira Receives U.S. Patent Approval for the ART500 Core Technology appeared first on MedTech Intelligence.